drugset
drugset / Trial / NCT04355039

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

NCT04355039 ↗

Phase 1 Withdrawn Medical College of Wisconsin
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a prospective, single-center, open-label phase Ib study aimed at determining a recommended phase II dose of INCB053914 and pomalidomide with dexamethasone. The trial will follow a 3 + 3 phase I dose-escalation design.

Timeline

Start
2021-07-01
Primary completion
2023-07-01
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB053914 Unknown 50 mg —
Subject INCB053914 Unknown 65 mg —
Subject INCB053914 Unknown 80 mg —
Background Dexamethasone Small molecule 40 mg —
Background Pomalidomide Other / unclassified 4 mg —

Indications

refractory plasma cell neoplasm